Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.82) by $0.13, FiscalAI reports. Agios Pharmaceuticals had a negative net margin of 764.01% and a negative return on equity of 31.07%. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.91 million. The business’s revenue for the quarter was up 137.7% compared to the same quarter last year.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• AQVESME U.S. launch off to a strong start with $20.7M in Q1 mitapivat net revenues (US $18.8M) and 242 prescriptions by REMS‑certified physicians as of March 31, though management cautioned early prescriptions reflect highly motivated patients and average initiation timelines are expected to normalize to ~10–12 weeks.
• Agios plans to submit an sNDA for mitapivat in sickle cell disease in Q2 under the U.S. Accelerated Approval pathway after productive pre‑sNDA discussions with the FDA and alignment on a confirmatory trial design.
• Multiple near‑term pipeline catalysts could drive upside, including phase II‑B tebapivat top‑line data in lower‑risk MDS (H1 2026), phase II tebapivat data in sickle cell disease (H2 2026), and early healthy volunteer data for AG‑236 (H1 2026).
• Financial position and discipline support execution — operating expense guidance for 2026 is expected to be approximately flat versus 2025, while the company ended Q1 with over $1 billion in cash, equivalents and marketable securities to fund launches and development.

Agios Pharmaceuticals Stock Up 14.5%

NASDAQ AGIO traded up $3.58 during trading hours on Wednesday, hitting $28.38. The company had a trading volume of 1,805,341 shares, compared to its average volume of 1,014,898. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The business has a fifty day simple moving average of $29.87 and a 200-day simple moving average of $31.07. The firm has a market cap of $1.69 billion, a P/E ratio of -4.00 and a beta of 0.79.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Citigroup upped their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. HC Wainwright cut their target price on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, JPMorgan Chase & Co. upped their target price on Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Monday, April 6th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $41.78.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Krishnan Viswanadhan sold 2,959 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tsveta Milanova sold 3,262 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the transaction, the insider directly owned 46,829 shares of the company’s stock, valued at approximately $1,625,434.59. The trade was a 6.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 15,582 shares of company stock valued at $520,405 over the last three months. 4.93% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AGIO. T. Rowe Price Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $25,000. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $49,000. Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth $79,000. Finally, Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth $133,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.